Comparison of Bacillus Clausii and Saccharomyces Boulardii for Acute Diarrhea at Day 3
Comparison of the Clinical Efficacy of Bacteria-Based Probiotics to Fungi-Based Probiotics in Acute Watery Diarrhea in Pediatric Outpatient Department
THIS STUDY WILL BE CONDUCTED ON OPD PATIENTS IN CENTRAL PARK TEACHING HOSPITAL LAHORE TO SEE THE EFFECT OF PROBIOTICS ON DIARRHEA ALL PATIENTS INCLUDED WILL HAVE ACUTE WATERY DIARRHEA AND THE OUTCOME WILL BE CHECKED ON THE THIRD DAY OF ADMISSION
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study is planning to compare the clinical efficacy of bacterial ( Bacillus clausii) versus fungal (Sacchromyces boulardii) probiotic in acute watery diarrhea. A clear consensus has not been reached regarding the use of appropriate probiotic. Some pediatricians are of the opinion that bacterial probiotic are suprerior to fungal probiotics along with rehydration for improvement of diarrhea. However, others experience is that fungal probiotics are better along with rehydration for the improvement of diarrhea. A high-quality evidence basis must be established that guides the pediatrician regarding the choice of probiotic.The results of this study will help guide pediatricians to the better probiotic for the clinical improvement of acute diarrhea in our setup.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- Central Park Teaching Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Children aged 0 to 59 months
- Acute Watery Diarrhea
- The child's parents or caregiver understands, agrees to participate, and complies with the study protoco
Exclusion Criteria:
- Patients with bloody diarrhea, severe dehydration, severe electrolyte imbalance, immunocompromised children, or malabsorption disorders and systemic illnesses (sepsis, pneumonia, urinary infections)
- Those who have already used antibiotics or probiotics during this illness
- Known hypersensitivity to probiotics
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: BACILLUS CLAUSII
Participants will receive bacterial-based probiotic Bacillus clausii (2 billion spores), administered orally twice daily, in addition to standard diarrheal treatment. Participants will be followed for 3 days to assess clinical efficacy based on stool frequency and consistency. |
Bacillus clausii, a bacterial-based probiotic, will be administered orally at a dose of 2 billion spores twice daily for 3 days, in addition to standard diarrheal treatment. Clinical efficacy will be assessed on the 3rd day based on stool frequency and consistency. |
|
Comparatore attivo: SACCHROMYCES BOULARDII
Participants will receive fungal-based probiotic Saccharomyces boulardii 250 mg, administered orally twice daily, in addition to standard diarrheal treatment. Participants will be followed for 3 days to assess clinical efficacy based on stool frequency and consistency. |
Saccharomyces boulardii, a fungal-based probiotic, will be administered orally at a dose of 250 mg twice daily for 3 days, in addition to standard diarrheal treatment. Clinical efficacy will be assessed on the 3rd day based on stool frequency and consistency. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinical efficacy of probiotic treatment
Lasso di tempo: 3 days
|
Clinical efficacy will be assessed on the 3rd day. A positive outcome will be defined as ≤3 episodes of stool with Bristol stool grade 5 or less. The clinical efficacy of Bacillus clausii will be compared with Saccharomyces boulardii in children with acute watery diarrhea. |
3 days
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Awais M, Alam S, Wali N, Mehmood R, Nasir U, Waheed A. Comparison of the Clinical Efficacy of Bacteria-Based Probiotics to Fungi-Based Probiotics. 7.
- Sharif A, Ardakani AT, Kashani HH, Rabiee F, Sharif MR. Comparison Efficacy of Bacterial and Fungal Probiotics on Acute Pediatric Diarrhea A Randomized Clinical Trial [Internet]. 2019 [cited 2024 Sept 3]. Available from: https://www.researchsquare.com/article/rs-2183/v1
- Erdogan O, Tanyeri B, Torun E, Gonullu E, Arslan H, Erenberk U, Oktem F. The comparition of the efficacy of two different probiotics in rotavirus gastroenteritis in children. J Trop Med. 2012;2012:787240. doi: 10.1155/2012/787240. Epub 2012 Jun 19.
- Khan MH, Khan MS. Comparison of Multispecies Probiotic and Saccahomyces Boulardii in Children with Acute Watery Diarrhea in Terms of Mean Duration of Diarrhea.
- Sharma AK, Puri N, Mathur M, Mathur A. A randomized controll trial to compare the efficacy of saccharomyces boulardii, bacillus clausii, and lactobacillus rhamnosus GG preparation in the treatment of acute diarrhea in children. Asian J Pharm Clin Res. 2022 Mar 14;63-7.
- Syed M, Gondi S, D V, P U. Study on efficacy of probiotic use in pediatric acute diarrhea: A prospective open-labeled study. Natl J Physiol Pharm Pharmacol. 2023;14(5):1
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CPMC/IRB-No/1503
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .